

## **Karolinska Development's portfolio company Aprea Therapeutics presents initial results from the ongoing phase Ib/II study with APR-246 and azacitidine (AZA) for the treatment of Mutant Myelodysplastic Syndromes (MDS) at the cancer congress AACR**

**STOCKHOLM – 16 April 2018.** Karolinska Development AB (Nasdaq Stockholm: KDEV) today announces that its portfolio company Aprea Therapeutics is presenting initial positive results at the 2018 American Association of Cancer Research (AACR) Annual Meeting in Chicago from its ongoing Phase Ib/II clinical study of APR-246 in MDS patients. The ongoing study evaluates the safety and efficacy of APR-246 in combination with azacytidine for the treatment of *TP53* mutated MDS.

The overall response rate (ORR) in 8 evaluable patients was 100%, with 6 patients achieving a complete response (CR) and 2 patients achieving a marrow CR (mCR). Median progression free survival (PFS) and overall survival (OS) have yet not been reached in the study, and no responding patients have experienced relapse.

At data cutoff, 4 CR patients had complete cytogenetic response, with results of additional CR patients pending analysis.

Adverse events (AEs) during the APR-246 monotherapy lead-in phase were all grade 1. No dose-limiting toxicities have been experienced to date.

“These initial results are very encouraging and we are looking forward to see the full results from the study and the benefits it can give to MDS patients”, said Viktor Drvota, CEO of Karolinska Development.

For more information about the study and the results, please visit [www.aprea.com](http://www.aprea.com)

### **For further information, please contact:**

Viktor Drvota, CEO, Karolinska Development AB

Phone: +46 73 982 52 02, e-mail: [viktor.dravota@karolinskadevelopment.com](mailto:viktor.dravota@karolinskadevelopment.com)

### **TO THE EDITORS**

#### **About Aprea Therapeutics**

Aprea Therapeutics is a Boston, Massachusetts- and Stockholm, Sweden-based biopharmaceutical company focused on the discovery and development of novel anticancer compounds that reactivate the tumor suppressor protein, p53. The Company's lead drug candidate is APR-246, a first-in-class small molecule in clinical development for platinum-sensitive high-grade serious ovarian cancer, platinum-resistant high-grade serious ovarian cancer; myelodysplastic syndrome (MDS); esophageal cancer; and melanoma.

**About Karolinska Development AB**

Karolinska Development AB (Nasdaq Stockholm: KDEV) is a Nordic life sciences investment company. The company focuses on identifying breakthrough medical innovations and invests in the creation and growth of companies that advance these assets into commercial products that are designed to make a difference to patients' lives while providing an attractive return on investment to shareholders.

Karolinska Development has access to world-class medical innovations at the Karolinska Institutet and other leading universities and research institutes in the Nordic region. The Company aims to build companies around scientists who are leaders in their fields, supported by experienced management teams and advisers, and co-funded by specialist international investors, to provide the greatest chance of success.

Karolinska Development has established a portfolio of nine companies targeting opportunities in innovative treatment for life-threatening or serious debilitating diseases.

The Company is led by an entrepreneurial team of investment professionals with a proven track record as company builders and with access to a strong global network.

For more information, please visit [www.karolinskadevelopment.com](http://www.karolinskadevelopment.com)

*This information is information that Karolinska Development AB (publ) (Nasdaq Stockholm: KDEV) is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of Viktor Drvota, at 14:59 CET on 16 April 2018.*